CoChat
Sign Up
Cited by 88Genomics and Chromatin DynamicsViral-associated cancers and disordersCancer-related molecular mechanisms research

Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation

Open access
Liang, Jun, Zhou, Hufeng, Gerdt, Catherine, Tan, Min, Colson, Tyler, Kaye, Kenneth M., Kieff, Elliott, Zhao, Bo·2016·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.1616697113PMC PMC5150416
Open this paper in CoChat — free accountOpen PDF

Abstract

Significance: EBV infection causes African Burkitt's lymphoma; Hodgkin's disease; lymphomas in immune suppressed people, including HIV infected people; nasopharyngeal carcinoma; and ∼10% of gastric carcinomas. We recently found EBV super-enhancer (ESE) to be critical for lymphoblastoid cell (LCL) growth and survival. We now identified an ESE constituent, enhancer RNA (eRNA), that is important for ESE function. These eRNAs were activated by viral transactivator, EBV nuclear antigen 2 (EBNA2). MYC oncogene ESE eRNAs were able to enhance ESE activation of MYC expression and are essential for LCL growth. Targeting ESE eRNAs may lead to new therapeutics for EBV-associated malignancies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1616697113

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Knockdown of selected enhancer RNAs reduces expression of the corresponding gene targets, suggesting functionality.

    “However, studies that knock down selected eRNA have found reduced expression of the corresponding gene targets, suggesting functionality [79–81].”

    From Transcriptional enhancers and their communication with gene promoters (2021) · cites this paper as [79]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's Lymphoma. Lancet 1(7335):702-703.
  2. Longnecker R, Kieff E, Cohen JI (2013) Epstein-Barr Virus (Lippincott Williams & Wilkins, Philadelphia) 8th Ed, pp 1898-1959.
  3. Cohen JI, Wang F, Mannick J, Kieff E (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 86(23): 9558-9562.
  4. Hammerschmidt W, Sugden B (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340(6232):393-397.
  5. Kaye KM, Izumi KM, Kieff E (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90(19): 9150-9154.
  6. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E (1991) The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lympho- cyte transformation. J Virol 65(12):6826-6837.
  7. Tomkinson B, Robertson E, Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67(4): 2014-2025.
  8. Alfieri C, Birkenbach M, Kieff E (1991) Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181(2):595-608.
  9. Kaiser C, et al. (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73(5):4481-4484.
  10. Kempkes B, et al. (1995) B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 14(1):88-96.
  11. Zhao B, et al. (2011) Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci USA 108(36): 14902-14907.
  12. Maruo S, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lym- phoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci USA 108(5):1919-1924.
  13. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EB- NA3C with CtBP. PLoS Pathog 6(6):e1000951.
  14. Skalska L, et al. (2013) Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 9(2):e1003187. Myc eRNA 428 eRNA 525
  15. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lympho- blastoid cells. Proc Natl Acad Sci USA 97(11):6055-6060.
  16. Wang F, Kikutani H, Tsang SF, Kishimoto T, Kieff E (1991) Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J Virol 65(8):4101-4106.
  17. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64(7):3407-3416.
  18. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA 91(16):7568-7572.
  19. Ling PD, Rawlins DR, Hayward SD (1993) The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA 90(20):9237-9241.
  20. Tong X, Wang F, Thut CJ, Kieff E (1995) The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding pro- tein. J Virol 69(1):585-588.
  21. Harada S, Kieff E (1997) Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 71(9):6611-6618.
  22. Portal D, et al. (2011) EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding. Proc Natl Acad Sci USA 108(19):7808-7813.
  23. Jiang S, et al. (2014) Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/ IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci USA 111(1):421-426.
  24. Ohashi M, et al. (2015) The EBNA3 family of Epstein-Barr virus nuclear proteins as- sociates with the USP46/USP12 deubiquitination complexes to regulate lympho- blastoid cell line growth. PLoS Pathog 11(4):e1004822.
  25. Schmidt SC, et al. (2015) Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes. Proc Natl Acad Sci USA 112(2):554-559.
  26. Zhou H, et al. (2015) Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 17(2):205-216.
  27. Sigova AA, et al. (2015) Transcription factor trapping by RNA in gene regulatory el- ements. Science 350(6263):978-981.
  28. Pnueli L, Rudnizky S, Yosefzon Y, Melamed P (2015) RNA transcribed from a distal enhancer is required for activating the chromatin at the promoter of the gonado- tropin α-subunit gene. Proc Natl Acad Sci USA 112(14):4369-4374.
  29. Yu M, et al. (2015) RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science 350(6266):1383-1386.
  30. Core LJ, et al. (2014) Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers. Nat Genet 46(12): 1311-1320.
  31. Robinson JT, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29(1):24-26.
  32. Itzen F, Greifenberg AK, Bösken CA, Geyer M (2014) Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res 42(12):7577-7590.
  33. Zhao B, et al. (2006) RNAs induced by Epstein-Barr virus nuclear antigen 2 in lym- phoblastoid cell lines. Proc Natl Acad Sci USA 103(6):1900-1905.
  34. Mifsud B, et al. (2015) Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat Genet 47(6):598-606.
  35. Whyte WA, et al. (2013) Master transcription factors and mediator establish super- enhancers at key cell identity genes. Cell 153(2):307-319.
  36. Jeon Y, Lee JT (2011) YY1 tethers Xist RNA to the inactive X nucleation center. Cell 146(1):119-133.
  37. Lee N, Moss WN, Yario TA, Steitz JA (2015) EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA. Cell 160(4):607-618.
  38. Hallier M, Tavitian A, Moreau-Gachelin F (1996) The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54nrb. J Biol Chem 271(19): 11177-11181.
  39. Bayer TS, Booth LN, Knudsen SM, Ellington AD (2005) Arginine-rich motifs present multiple interfaces for specific binding by RNA. RNA 11(12):1848-1857.
  40. Tong X, Yalamanchili R, Harada S, Kieff E (1994) The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J Virol 68(10):6188-6197.
  41. Li W, et al. (2013) Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498(7455):516-520.
  42. Zhang N, et al. (2008) A handcuff model for the cohesin complex. J Cell Biol 183(6): 1019-1031.
  43. Chapuy B, et al. (2013) Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24(6):777-790.
  44. Lai F, Gardini A, Zhang A, Shiekhattar R (2015) Integrator mediates the biogenesis of enhancer RNAs. Nature 525(7569):399-403.

Cited by

Sorted by citations

Authors
Liang, J., Zhou, H., Gerdt, C., Tan, M., Colson, T., Kaye, K. M., Kieff, E., & Zhao, B.
Affiliations
Brigham and Women's Hospital (US)
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
2016-11-18
Volume
113
Issue
49
Pages
14121-14126
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.1616697113
PMC
PMC5150416
OpenAlex
W2556468356
Cited by
88
References
2
Citations by year
2025: 7 · 2024: 7 · 2023: 12 · 2022: 11 · 2021: 18 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 9
FWCI
3.81
Type
journal article
Language
en
Open access
Licence
www.pnas.org/site/misc/userlicense.xhtml (vor, 181 d)
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • HHS | NIH | National Cancer Institute (R01CA047006, R01CA085180, R01CA170023)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI123420)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
Epstein-Barr virus, super-enhancers, enhancer RNA, MYC oncogene, lymphoblastoid cell lines, EBNA2, BRD4, enhancer looping, H3K27ac, cell proliferation, transcription start sites, chromatin looping
MeSH terms
Bromodomain Containing Proteins, Cell Line, Endonucleases, Enhancer Elements, Genetic, Herpesvirus 4, Human, Humans, Lymphoproliferative Disorders, Nuclear Proteins, Transcription Factors, Proto-Oncogene Proteins c-myc, Cell Cycle Proteins, Host-Pathogen Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review